SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NAUT reported Third Quarter 2026 results. The price and volatility reaction is pending.
NAUTearnings

Earnings reactions, page 12

Nautilus Biotechnology, Inc. (NAUT) Q3 FY2026 earnings

October 27, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $0.2 million for the third quarter of 2026.
  • Operating expenses were $16.9 million for the third quarter of 2026.
  • Net loss was $15.6 million for the third quarter of 2026.
  • Cash, cash equivalents, and investments were $114.3 million as of September 30, 2026.
  • Net loss per share attributable to common stockholders, basic and diluted was $(0.12) for the third quarter of 2026.

Guidance

  • Nautilus expects to receive up to $6 million to deploy its Voyager Platform to measure proteoforms driving Alzheimer’s disease and cancer.
  • Planned instrument availability in the middle of 2027.
  • Advanced the proteoform pipeline needed to deliver twenty assays planned through mid-2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-26 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →